Summit Therapeutics (MEX:SMMT) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Summit Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Summit Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.

Summit Therapeutics's long-term debt to total assets ratio declined from Dec. 2023 (0.51) to Dec. 2024 (0.01). It may suggest that Summit Therapeutics is progressively becoming less dependent on debt to grow their business.

Summit Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Summit Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics LT-Debt-to-Total-Asset Chart

Summit Therapeutics Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.75

0.51

0.01

Summit Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.51	0.60	0.02	0.01	0.01

Summit Therapeutics LT-Debt-to-Total-Asset Calculation

Summit Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	72.015	/	9083.909
	=

Summit Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	72.015	/	9083.909
	=

Summit Therapeutics (MEX:SMMT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Summit Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (MEX:SMMT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SMMT:USA

Address

601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.